Peering Into Dermata Therapeutics's Recent Short Interest
Portfolio Pulse from Benzinga Insights
Dermata Therapeutics (NYSE:DRMA) has seen a significant rise in short interest, with a 141.25% increase since its last report. The company now has 52 thousand shares sold short, representing 9.65% of its float. This is higher than the peer group average of 9.44%. The increase in short interest could indicate bearish sentiment among investors.
August 07, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Dermata Therapeutics has experienced a 141.25% increase in short interest, now at 9.65% of its float. This could indicate bearish sentiment among investors.
The significant rise in short interest suggests that more investors are betting against the stock, which could lead to downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100